公开(公告)号：US20140163052A1

公开(公告)日：2014-06-12

申请号：US14088796

申请日：2013-11-25

Applicant: AMGEN INC.

Inventor： Xiaoqi Chen ,  Kang Dai ,  Jason Duquette ,  Michael W. Gribble, JR. ,  Justin N. Huard ,  Kathleen S. Keegan ,  Zhihong Li ,  Sarah E. Lively ,  Lawrence R. McGee ,  Mark L. Ragains ,  Xianghong Wang ,  Margaret F. Weidner ,  Jian Zhang

IPC: C07D471/14

CPC classification number: C07D519/00 ,  C07D471/14

Abstract: Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure: where R1 is a group of Formula IA, Formula IB, Formula IC, or Formula ID and the definitions of the other variables are provided herein.

Abstract translation: 式I化合物是CDK 4，CDK 6和FLT 3的有用抑制剂。 这些化合物可用于治疗癌症和各种其他疾病状况。 式I的化合物具有以下结构：其中R1是式IA，式IB，式IC或式ID的基团，并且本文提供了其它变量的定义。

公开(公告)号：US09359355B2

公开(公告)日：2016-06-07

申请号：US14088796

申请日：2013-11-25

Applicant: AMGEN INC.

Inventor： Xiaoqi Chen ,  Kang Dai ,  Jason Duquette ,  Michael W. Gribble, Jr. ,  Justin N. Huard ,  Kathleen S. Keegan ,  Zhihong Li ,  Sarah E. Lively ,  Lawrence R. McGee ,  Mark L. Ragains ,  Xianghong Wang ,  Margaret F. Weidner ,  Jian Zhang

IPC: C07D471/14 ,  C07D519/00

CPC classification number: C07D519/00 ,  C07D471/14

Abstract: Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure: where R1 is a group of Formula IA, Formula IB, Formula IC, or Formula ID and the definitions of the other variables are provided herein.

Abstract translation: 式I化合物是CDK 4，CDK 6和FLT 3的有用抑制剂。 这些化合物可用于治疗癌症和各种其他疾病状况。 式I的化合物具有以下结构：其中R1是式IA，式IB，式IC或式ID的基团，并且本文提供了其它变量的定义。

公开(公告)号：US20130273024A1

公开(公告)日：2013-10-17

申请号：US13851019

申请日：2013-03-26

Applicant: Amgen Inc.

Inventor： Frank KAYSER ,  Marc Labelle ,  Bei Shan ,  Jian Zhang ,  Mingyue Zhou

IPC: C12N9/10 ,  C07D403/12 ,  C07D417/12

CPC classification number: C12N9/1029 ,  A61K31/497 ,  A61K38/45 ,  C07D403/12 ,  C07D417/12

Abstract: The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, inflammation, thrombosis and other conditions and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide.

Abstract translation: 本发明提供了通过改变LCAT多肽来治疗动脉粥样硬化，炎症，血栓形成和其它病症并降低或预防受试者胆固醇积聚的化合物，药物组合物和方法。